Dyne Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -550 | -521 | ||
EBITDA | -187,003 | -173,401 | -116,102 | -101,229 |
EBIT | -187,603 | -173,961 | -116,652 | -101,750 |
Net Income | -193,552 | -178,556 | -120,854 | -111,955 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -179,502 | -131,800 | -145,143 | -112,316 |
Cash | 913,203 | 676,114 | 753,102 | 893,369 |
Basic Shares | 181,765 | 165,451 | 165,036 | 128,442 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -2,049 | -2,243 | -2,461 | -3,345 |
EBITDA | -437,973 | -315,745 | -234,264 | -169,279 |
EBIT | -440,022 | -317,418 | -235,937 | -170,962 |
Net Income | -446,214 | -317,418 | -235,937 | -165,237 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -405,127 | -294,745 | -188,887 | -156,712 |
Cash | 893,369 | 435,449 | 121,626 | 172,147 |
Basic Shares | 128,442 | 94,144 | 59,683 | 51,976 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$1.06 |
2026-06-30 | -$1.08 |
2026-03-31 | -$0.73 |
2025-12-31 | -$0.73 |